New drug cocktails tested for advanced cancers: hope or hype?
NCT ID NCT03307785
First seen Oct 31, 2025 · Last updated Jun 23, 2026 · Updated 37 times
Summary
This early-phase trial tested several combinations of cancer drugs, including niraparib, TSR-042, bevacizumab, and various chemotherapies, in 60 patients with advanced or metastatic cancer. The main goal was to find safe doses for future studies. The trial has been completed, but results are not yet widely available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
GSK Investigational Site
Scottsdale, Arizona, 85258, United States
-
GSK Investigational Site
Encinitas, California, 92024, United States
-
GSK Investigational Site
San Marcos, California, 92069, United States
-
GSK Investigational Site
Sarasota, Florida, 34232, United States
-
GSK Investigational Site
Canton, Ohio, 44718, United States
-
GSK Investigational Site
Cleveland, Ohio, 44106, United States
-
GSK Investigational Site
Nashville, Tennessee, 37203, United States
-
GSK Investigational Site
Houston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
niraparib, TSR-042, bevacizumab, carboplatin, paclitaxel, pemetrexed, nab-paclitaxel, TSR-022
What this could lead to
If successful, this could point toward safer, more effective drug combinations for advanced cancers, potentially improving disease control.
What could go wrong
This is a very early (Phase 1) dose-finding study with only 60 participants. The combinations may cause serious side effects and may not work against the cancer.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.